Cambium Bio (ASX: CMB) has received approval from the US Food and Drug Administration (FDA) for a protocol relating to Phase ...

A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates ...

More than 2 years after the child was born, no identifiable features of SMA have been observed, reported Richard Finkel, MD, of St. Jude Children's Research Hospital in Memphis, Tennessee, and ...

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...